Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

Tesamorelin Review 2026: Comparison Table

The table below compares tesamorelin to other peptide-based strategies for visceral fat reduction, growth hormone modulation, and metabolic support. Each option represents a distinct mechanism. GHRH agonism, ghrelin mimicry, GLP-1 agonism, and GH secretagogue

This comparison does not assign a generated winner or score.

  • The table below compares tesamorelin to other peptide-based strategies for visceral fat reduction, growth hormone modulation, and metabolic support. Each option represents a distinct mechanism. GHRH agonism, ghrelin mimicry, GLP-1 agonism, and GH secretagogue stacking.
  • Tesamorelin
  • GHRH receptor agonist. Stimulates endogenous pulsatile GH release from pituitary
  • Visceral adipose tissue reduction in HIV lipodystrophy
  • 2mg daily subcutaneous injection, evening preferred
  • 15–20% VAT reduction at 26 weeks in Phase 3 RCTs
  • FDA-approved, multiple Phase 3 trials published in Lancet and AIDS journals
  • Gold standard for visceral fat reduction. Most robust clinical evidence, FDA approval, and safety profile. Ideal for targeted VAT loss without appetite suppression.
  • MK-677 (Ibutamoren)
  • Ghrelin receptor agonist. Stimulates GH and IGF-1 without pituitary GHRH pathway
  • Investigational for muscle wasting, bone density
  • 25mg daily oral dosing
  • Limited VAT-specific data; increases lean mass but inconsistent fat loss
  • Phase 2 trials only; no FDA approval for any indication
  • Oral convenience is the primary advantage, but lacks VAT-specific efficacy data. Higher rates of water retention and increased appetite make fat loss outcomes inconsistent.
  • Ipamorelin
  • Growth hormone secretagogue. Stimulates GH release via ghrelin-independent pathway
  • Research peptide for GH modulation
  • 200–300mcg per injection, 2–3× daily subcutaneous
  • No published VAT-specific trials; anecdotal fat loss reported
  • Preclinical and early-phase human trials only
  • Shorter half-life requires multiple daily injections. May synergize with GHRH agonists like tesamorelin in stacked protocols but lacks standalone VAT evidence.
  • Tirzepatide (GLP-1/GIP)
  • Dual GLP-1 and GIP receptor agonist. Slows gastric emptying, enhances insulin sensitivity
  • Type 2 diabetes and obesity (FDA-approved)
  • 5–15mg weekly subcutaneous injection
  • 15–22% total body weight reduction in SURMOUNT trials; VAT loss proportional to total weight loss
  • Phase 3 RCTs, FDA-approved
  • Produces greater total weight loss than tesamorelin but via appetite suppression and caloric deficit. Not selective VAT targeting. Best for patients needing whole-body fat loss and metabolic control.
  • CJC-1295 + Ipamorelin Stack
  • GHRH analog (CJC-1295) + ghrelin-independent GH secretagogue (Ipamorelin)
  • Synergistic GH pulse amplification
  • CJC-1295: 1–2mg weekly; Ipamorelin: 200–300mcg 2–3× daily
  • No published VAT-specific trials; anecdotal reports of enhanced body composition
  • Preclinical and anecdotal evidence only
  • Theoretical synergy between GHRH and non-ghrelin GH pathways. Lack of controlled human trials makes efficacy and safety profile speculative.
  • The core distinction: tesamorelin is the only peptide in this comparison table with FDA approval and published Phase 3 randomized controlled trial evidence specifically demonstrating visceral adipose tissue reduction. Other approaches may increase growth hormone levels or reduce total body weight, but visceral fat selectivity is unique to tesamorelin's GHRH mechanism.
  • For researchers exploring multi-pathway GH modulation, Real Peptides offers a comprehensive Tesamorelin Ipamorelin Growth Hormone Stack designed for investigational protocols requiring synergistic GH secretagogue activity. You can also explore our complete Shop All Peptides collection for additional research-grade compounds verified through third-party HPLC analysis.